CJC-1295

About the Product

Genetic Labs CJC-1295 is a high-purity synthetic peptide (research grade) supplied in a vial containing 10mg of lyophilized (freeze-dried) powder. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 30 amino acids. It is a potent and long-acting growth hormone secretagogue that stimulates the pituitary gland to release endogenous growth hormone (GH). CJC-1295 is modified with a drug affinity complex (DAC) —a chemical moiety that enables binding to plasma proteins such as albumin—significantly extending its half-life and duration of action compared to native GHRH. This makes it a valuable research tool for studying the growth hormone axis, metabolic regulation, and tissue repair.

Kit Contents:

• 1 Vial with 10mg CJC-1295 (Lyophilized Powder)

• 1 Vial with 3mL Bacteriostatic Water (Diluent)

For Laboratory Research Use Only. Not for human consumption.

Benefits (Research Scope)

• GHRH Analog with Extended Half-Life: CJC-1295 is a synthetic analog of GHRH that incorporates a drug affinity complex (DAC) for albumin binding, resulting in significantly prolonged half-life and sustained release of growth hormone. This makes it ideal for studying the effects of stable, long-acting GHRH receptor activation.

• Versatile Research Tool: Suitable for a wide range of studies, including:

  • Endocrinology: Research into growth hormone regulation, the hypothalamic-pituitary-somatotropic axis, and growth hormone deficiency.

  • Muscle Physiology: Studies on muscle growth, protein synthesis, muscle wasting conditions (sarcopenia, cachexia), and recovery.

  • Metabolic Disorders: Research into glucose metabolism, lipid metabolism, insulin sensitivity, and obesity.

  • Aging Research: Investigation into age-related decline in GH and IGF-1 levels (somatopause), cellular senescence, and interventions to promote healthy aging.

  • Bone & Cartilage Research: Studies on bone formation, bone mineral density, and osteoporosis.

  • Tissue Regeneration: Research into wound healing, tissue repair, and organ regeneration.

  • Neurobiology: Studies on neuroprotection, cognitive function, and neural regeneration.

  • Sleep Research: Investigation into the relationship between GH secretion and sleep patterns.

• Practical Formulation: The lyophilized powder ensures stability and extended shelf life, while the included bacteriostatic water facilitates easy reconstitution for both in vitro and in vivo experiments.

Research & Science

CJC-1295 is one of the most extensively studied long-acting GHRH analogs, with a robust body of preclinical and clinical research supporting its mechanism and applications.

• Mechanism of Action: CJC-1295 is a 30-amino-acid peptide analog of human GHRH that acts as a potent agonist at the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary. The key features of its mechanism include:

  • GHRH Receptor Activation: Binds to and activates GHRH-R, stimulating the cAMP-dependent signaling pathway.

  • Growth Hormone Release: Induces the synthesis and pulsatile release of endogenous growth hormone (GH) from the pituitary gland.

  • IGF-1 Elevation: The released GH stimulates hepatic production of insulin-like growth factor-1 (IGF-1), mediating many of the anabolic and metabolic effects.

  • Drug Affinity Complex (DAC): The DAC moiety enables reversible binding to plasma albumin, protecting the peptide from rapid degradation and renal clearance, resulting in:

    • Extended half-life (approximately 6-8 days in humans).

    • Sustained GH release with a more stable pharmacokinetic profile.

    • Reduced dosing frequency compared to native GHRH.

• Comparison to Native GHRH: Native GHRH has a very short half-life (approximately 7 minutes) due to rapid enzymatic degradation. CJC-1295's DAC modification represents a significant advancement, enabling prolonged receptor activation and sustained biological effects.

• Muscle & Bone Research: Studies have demonstrated that CJC-1295:

  • Promotes muscle growth and protein synthesis in animal models.

  • Enhances bone mineral density and stimulates bone formation markers.

  • May protect against age-related muscle loss (sarcopenia) .

• Metabolic Research: CJC-1295 has been shown to:

  • Promote lipolysis (fat breakdown) and fatty acid oxidation.

  • Improve metabolic efficiency and energy utilization.

  • Potentially improve insulin sensitivity in research models.

• Aging Research: The age-related decline in GH and IGF-1 levels (somatopause) is associated with:

  • Sarcopenia (age-related muscle loss).

  • Osteoporosis (reduced bone density).

  • Increased adiposity and metabolic dysfunction.

  • Decreased tissue repair and regenerative capacity.

  • CJC-1295 is being investigated for its potential to counteract these age-related changes through GH restoration.

• Sleep Research: GH secretion is closely linked to sleep, with the majority of GH released during slow-wave sleep. CJC-1295's effects on GH pulsatility make it a valuable tool for studying sleep-endocrinology interactions.

• Clinical Research Context: CJC-1295 has been evaluated in clinical trials for growth hormone deficiency and other indications, demonstrating:

  • Dose-dependent increases in GH and IGF-1 levels.

  • Favorable safety and tolerability profiles.

  • Sustained effects with once-weekly or bi-weekly dosing.

• Focus on Genetic Variability: Research is exploring how genetic polymorphisms in the GHRH receptor (GHRHR) gene, GH1 gene, IGF-1 gene, and related signaling pathways may influence individual responses to CJC-1295, providing insights for personalized approaches to GH-related research.